Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | TK1 | P04183 | 2/20 | 0.60 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibacitabine SCHEMBL5981937 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL21423094 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL225403 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL5981939 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL13812993 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL887475 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| Ibacitabine SCHEMBL225402 | 1.00 | DNMT1 (0.63) | DNMT1ADRB1TK1DNMT3BLMNA | |
| SCHEMBL1635378 | 0.91 | DNMT1 (0.52) | DNMT1ADRB1TK1DNMT3BFPR2 | |
| SCHEMBL1635376 | 0.91 | DNMT1 (0.52) | DNMT1ADRB1TK1DNMT3BFPR2 | |
| Ibacitabine SCHEMBL9710365 | 0.91 | DNMT1 (0.54) | DNMT1ADRB1TK1DNMT3BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4401 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-12595280-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2026-04-07 | — | — | US | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | claimed |
| EP-3534910-B1 | RIFAMPICIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | POP TEST ONCOLOGY LLC (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260060964-A1 | METHODS AND COMPOSITIONS FOR TREATING SEPSIS | ANTIVIRUS THERAPEUTICS (US) | 2026-03-05 | — | — | US | claimed |
| US-20260041660-A1 | Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms | CHANG RICHARD L (US) | 2026-02-12 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| CN-1634584-A | Anti-cancer medicine composition containing antimetabolite | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | claimed |
| CN-1634586-A | Anti-cancer medicine composition | SHANDONG LANJIN BIOENGINEERING (CN) | 2005-07-06 | — | — | CN | claimed |
| WO-2005058226-A1 | DERMAL DRUG DELIVERY SYSTEM | MEDPHARM LIMITED (GB) | 2005-06-30 | — | — | WO | claimed |
| US-20050118272-A1 | Micronized pharmaceutical or nutraceutical powder with immediate release | GALENIX INNOVATIONS (FR) | 2005-06-02 | — | — | US | claimed |
| US-20050049220-A1 | Dosing regimen for Flaviviridae therapy | PHARMASSET, INC. | 2005-03-03 | — | — | US | claimed |
| WO-2005018330-A1 | DOSING REGIMEN FOR FLAVIVIRIDAE THERAPY | PHARMASSET, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20040132684-A1 | Polymeric nucleoside prodrugs | SAMPATH UMASHANKER (US) | 2004-07-08 | — | — | US | claimed |
| US-20030124191-A1 | Use of an immediate-release powder in pharmaceutical and nutraceutical compositions | GALENIX INNOVATIONS (FR) | 2003-07-03 | — | — | US | claimed |
| US-20020013287-A1 | Polymeric compounds useful as prodrugs | RELIABLE BIOPHARMACEUTICALS, INC. ST LOUIS MISSOURI | 2002-01-31 | — | — | US | claimed |
| WO-2001085751-A1 | POLYMERIC COMPOUNDS USEFUL AS PRODRUGS | RELIABLE BIOPHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | claimed |